Table 4:
The treatment response and clinical outcomes in our AML cohort of patients with del(7) only treated with or without Venetoclax with or without TP53 alterations.
| Characteristic | Overall, N = 136 | del(7) Tp53-alt1, Others N = 63 | del(7) Tp53-alt1, Ven N = 20 | del(7) Tp53-wt1, Others N = 42 | del(7) Tp53-wt1, Ven N = 11 | p-value2 |
|---|---|---|---|---|---|---|
| Age (years), Mean+/−SD; Median (Range) | 68.2+/−11.4; 70.1 (23.4 – 87.8) | 68.0+/−10.9; 68.5 (32.0 – 87.6) | 70.3+/−9.6; 70.6 (42.7 – 85.7) | 69.2+/−10.5; 71.1 (48.1 – 87.8) | 62.0+/−18.1; 69.0 (23.4 – 81.3) | 0.7 |
| Gender, n/N (%) | 0.3 | |||||
| Female | 60/136 (44%) | 33/63 (52%) | 9/20 (45%) | 15/42 (36%) | 3/11 (27%) | |
| Male | 76/136 (56%) | 30/63 (48%) | 11/20 (55%) | 27/42 (64%) | 8/11 (73%) | |
| Cytogenetics, n/N (%) | <0.001 | |||||
| Complex (>=3) | 93/136 (68%) | 60/63 (95%) | 18/20 (90%) | 13/42 (31%) | 2/11 (18%) | |
| Other (<3) | 43/136 (32%) | 3/63 (4.8%) | 2/20 (10%) | 29/42 (69%) | 9/11 (82%) | |
| ELN based on Cytogenetics, n/N (%) | ||||||
| Poor | 136/136 (100%) | 63/63 (100%) | 20/20 (100%) | 42/42 (100%) | 11/11 (100%) | |
| Secondary AML, n/N (%) | 0.8 | |||||
| De novo AML | 83/136 (61%) | 37/63 (59%) | 11/20 (55%) | 28/42 (67%) | 7/11 (64%) | |
| Secondary AML | 53/136 (39%) | 26/63 (41%) | 9/20 (45%) | 14/42 (33%) | 4/11 (36%) | |
| TP53 Mutations, n/N (%) | <0.001 | |||||
| TP53 wild type | 56/124 (45%) | 3/51 (5.9%) | 0/20 (0%) | 42/42 (100%) | 11/11 (100%) | |
| TP53 mutant | 68/124 (55%) | 48/51 (94%) | 20/20 (100%) | 0/42 (0%) | 0/11 (0%) | |
| Unknown | 12 | 12 | 0 | 0 | 0 | |
| Chr17/17p Loss, n/N (%) | 35/136 (26%) | 30/63 (48%) | 5/20 (25%) | 0/42 (0%) | 0/11 (0%) | <0.001 |
| Venetoclax, n/N (%) | <0.001 | |||||
| Others | 105/136 (77%) | 63/63 (100%) | 0/20 (0%) | 42/42 (100%) | 0/11 (0%) | |
| Venetoclax | 31/136 (23%) | 0/63 (0%) | 20/20 (100%) | 0/42 (0%) | 11/11 (100%) | |
| Intensity, n/N (%) | 0.14 | |||||
| High Intensity | 28/136 (21%) | 12/63 (19%) | 1/20 (5.0%) | 12/42 (29%) | 3/11 (27%) | |
| Low Intensity | 108/136 (79%) | 51/63 (81%) | 19/20 (95%) | 30/42 (71%) | 8/11 (73%) | |
| Best Response, n/N (%) | 0.2 | |||||
| CR | 53/136 (39%) | 20/63 (32%) | 8/20 (40%) | 21/42 (50%) | 4/11 (36%) | |
| CRi | 16/136 (12%) | 5/63 (7.9%) | 2/20 (10%) | 6/42 (14%) | 3/11 (27%) | |
| NR | 67/136 (49%) | 38/63 (60%) | 10/20 (50%) | 15/42 (36%) | 4/11 (36%) |
1
TP53-alt indicates patients with TP53 mutations, chr17 loss, or chr17p loss
2
Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test